Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung cancer in the phase 1b FURTHER trial.
|Articles|August 10, 2021
- CURE® Lung Cancer Heroes® 2020 Essay Book
- Volume 1
A Lung Legend
Author(s)Kristen Gurba
"Dr. Ramirez is passionate about lung cancer and his research," writes Kristen Gurba in a submission for the CURE® Lung Cancer Heroes® Award.
Advertisement
Dr. Robert Ramirez is a physician at the NOLANETS clinic at Ochsner Health. He has clinical and research interests in lung cancer, specifically non-small cell and small cell cancers, as well as neuroendocrine tumors of the lung, including diffuse, idiopathic, pulmonary, neuroendocrine, cell hyperplasia, typical and atypical carcinoids. He has given multiple presentations at national and international meetings on lung cancer and neuroendocrine tumors and has multiple peer-reviewed publications. He is a recognized thought leader in these fields. He splits his clinical and research duties between the Ochsner Lung Cancer Multidisciplinary Program and the Ochsner Kenner/LSU Multidisciplinary Neuroendocrine Clinic. He is active in clinical trial design as well as teaching fellows, residents and medical students.
Dr. Ramirez is passionate about lung cancer and his research.
Articles in this issue
about 5 years ago
A Dedicated Guide of Lung Cancer Careabout 5 years ago
The Power of Hope in Cancer Careabout 5 years ago
Becoming a Champion for Patients With Lung Cancerabout 5 years ago
Leading Through Research, Educationabout 5 years ago
Oncology Nurse Has a Passion for Advocacyabout 5 years ago
An Inspiring, Guiding Light Through Lung Cancerabout 5 years ago
Blessed to Have a Hero in Cancer Careabout 5 years ago
Unconventional Candidate For a Lung Cancer Heroabout 5 years ago
Small-Town Cancer Team, Big Successabout 5 years ago
Music Leads to Lung Cancer AwarenessAdvertisement
Related to this article
U.S. counties where more residents had medical debt in collections had higher rates of late-stage lung, head and neck, colorectal and several other cancers, according to a study of 2,958 counties published in October 2026 in JAMA Network Open.
Libtayo survival data, a rare positive osteosarcoma trial and new ADCs for breast, lung and stomach cancers are among ESMO 2026 abstracts to watch.
After 19 years of survivorship, one cancer survivor reflects on life's changing seasons, managing scan anxiety and finding support beyond treatment.
Psychiatrist Dr. Yesne Alici of Memorial Sloan Kettering Cancer Center answers questions about family relationships during cancer, from asking for help to talking with children and friends.
Among more than 12,000 cancer survivors 65 and older, those who stayed physically active after diagnosis tended to have lower health care costs, an American Cancer Society study published Oct. 21, 2026, in CANCER found.
The FDA grants traditional approval to Keytruda and Keytruda Qlex for TMB-H solid tumors, updating the threshold to at least 13 mutations per megabase.
Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Traditional Approval to Keytruda for TMB-H Solid Tumors
2
FDA Clears AI Tool Using MRI to Gauge Breast Cancer Recurrence
3
Why Cancer Screening Remains Important for Long-Term Cancer Survivors
4
Psychiatrist Answers Questions About Family and Relationships During Cancer
5